7:53 AM ET
8-K
Business Update
aTYR Pharma Business Update
aTyr Pharma reached alignment with the FDA on the protocol for a new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The global study is expected to enroll approximately 372 patients and initiate study-related activities in the fourth quarter of 2026.
- Counterparty
- FDA
- Term
- 54 weeks